These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 35053486)

  • 1. Efficacy and Safety of Trans-Arterial Yttrium-90 Radioembolization in Patients with Unresectable Liver-Dominant Metastatic or Primary Hepatic Soft Tissue Sarcomas.
    Testa S; Bui NQ; Wang DS; Louie JD; Sze DY; Ganjoo KN
    Cancers (Basel); 2022 Jan; 14(2):. PubMed ID: 35053486
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of Radioembolization in the Management of Liver-Dominant Metastatic Renal Cell Carcinoma: A Single-Center, Retrospective Study.
    Bibok A; Mhaskar R; Jain R; Zhang J; Frakes J; Hoffe S; El-Haddad G; Parikh N; Ahmed A; Fishman MN; Choi J; Kis B
    Cardiovasc Intervent Radiol; 2021 Nov; 44(11):1755-1762. PubMed ID: 34312688
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Incorporating Yttrium-90 trans-arterial radioembolization (TARE) in the treatment of metastatic pancreatic adenocarcioma: a single center experience.
    Kim AY; Unger K; Wang H; Pishvaian MJ
    BMC Cancer; 2016 Jul; 16():492. PubMed ID: 27430276
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combined Effects of Yttrium-90 Transarterial Radioembolization around Immunotherapy for Hepatic Metastases from Uveal Melanoma: A Preliminary Retrospective Case Series.
    Zheng J; Irani Z; Lawrence D; Flaherty K; Arellano RS
    J Vasc Interv Radiol; 2018 Oct; 29(10):1369-1375. PubMed ID: 30174161
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Transarterial Chemoembolization vs Radioembolization for Neuroendocrine Liver Metastases: A Multi-Institutional Analysis.
    Egger ME; Armstrong E; Martin RC; Scoggins CR; Philips P; Shah M; Konda B; Dillhoff M; Pawlik TM; Cloyd JM
    J Am Coll Surg; 2020 Apr; 230(4):363-370. PubMed ID: 32032719
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transarterial Radioembolization Treatment of Pancreatic Cancer Patients with Liver-Dominant Metastatic Disease Using Yttrium-90 Glass Microspheres: A Single-Institution Retrospective Study.
    Kayaleh R; Krzyston H; Rishi A; Naziri J; Frakes J; Choi J; El-Haddad G; Parikh N; Sweeney J; Kis B
    J Vasc Interv Radiol; 2020 Jul; 31(7):1060-1068. PubMed ID: 32534978
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Response and Overall Survival for Yttrium-90 Radioembolization of Hepatic Sarcoma: A Multicenter Retrospective Study.
    Miller MD; Sze DY; Padia SA; Lewandowski RJ; Salem R; Mpofu P; Haste PM; Johnson MS
    J Vasc Interv Radiol; 2018 Jun; 29(6):867-873. PubMed ID: 29724518
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Outcome and Safety after 103 Radioembolizations with Yttrium-90 Resin Microspheres in 73 Patients with Unresectable Intrahepatic Cholangiocarcinoma-An Evaluation of Predictors.
    Paprottka KJ; Galiè F; Ingrisch M; Geith T; Ilhan H; Todica A; Michl M; Nadjiri J; Paprottka PM
    Cancers (Basel); 2021 Oct; 13(21):. PubMed ID: 34771563
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Transarterial Yttrium-90 Glass Microsphere Radioembolization of Chemotherapy-Refractory Breast Cancer Liver Metastases: Results of a Single Institution Retrospective Study.
    Barakat E; Bibok A; Rishi A; Ahmed A; Frakes JM; Hoffe SE; Armaghani AJ; Soyano AE; Costa RLB; El-Haddad G; Choi J; Kis B
    Adv Radiat Oncol; 2022; 7(1):100838. PubMed ID: 35071835
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of a prognostic score to predict response to Yttrium-90 radioembolization for hepatocellular carcinoma with portal vein invasion.
    Spreafico C; Sposito C; Vaiani M; Cascella T; Bhoori S; Morosi C; Lanocita R; Romito R; Chiesa C; Maccauro M; Marchianò A; Mazzaferro V
    J Hepatol; 2018 Apr; 68(4):724-732. PubMed ID: 29331342
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Selective Internal Yttrium-90 Radioembolization Therapy (90Y-SIRT) Versus Best Supportive Care in Patients With Unresectable Metastatic Melanoma to the Liver Refractory to Systemic Therapy: Safety and Efficacy Cohort Study.
    Xing M; Prajapati HJ; Dhanasekaran R; Lawson DH; Kokabi N; Eaton BR; Kim HS
    Am J Clin Oncol; 2017 Feb; 40(1):27-34. PubMed ID: 25089529
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical Application of Trans-Arterial Radioembolization in Hepatic Malignancies in Europe: First Results from the Prospective Multicentre Observational Study CIRSE Registry for SIR-Spheres Therapy (CIRT).
    Helmberger T; Golfieri R; Pech M; Pfammatter T; Arnold D; Cianni R; Maleux G; Munneke G; Pellerin O; Peynircioglu B; Sangro B; Schaefer N; de Jong N; Bilbao JI; ;
    Cardiovasc Intervent Radiol; 2021 Jan; 44(1):21-35. PubMed ID: 32959085
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Outcomes of Radioembolization in Patients with Chemorefractory Colorectal Cancer Liver Metastasis: a Single-Center Experience.
    Türk G; Eldem G; Kılıçkap S; Bozkurt FM; Salancı BV; Çil BE; Peynircioğlu B; Yalçın Ş; Balkancı F
    J Gastrointest Cancer; 2019 Jun; 50(2):236-243. PubMed ID: 29354877
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Transarterial hepatic yttrium-90 radioembolization in patients with unresectable intrahepatic cholangiocarcinoma: factors associated with prolonged survival.
    Hoffmann RT; Paprottka PM; Schön A; Bamberg F; Haug A; Dürr EM; Rauch B; Trumm CT; Jakobs TF; Helmberger TK; Reiser MF; Kolligs FT
    Cardiovasc Intervent Radiol; 2012 Feb; 35(1):105-16. PubMed ID: 21431970
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Yttrium-90 Hepatic Radioembolization for Advanced Chemorefractory Metastatic Colorectal Cancer: Survival Outcomes Based on Right- Versus Left-Sided Primary Tumor Location.
    Wu V; Li MD; Goodwin JS; Wehrenberg-Klee EP; Zurkiya O; Kalva SP; Ganguli S
    AJR Am J Roentgenol; 2021 Nov; 217(5):1141-1152. PubMed ID: 33594907
    [No Abstract]   [Full Text] [Related]  

  • 16. Safety and Effectiveness of Yttrium-90 Radioembolization around the Time of Immune Checkpoint Inhibitors for Unresectable Hepatic Metastases.
    Ruohoniemi DM; Zhan C; Wei J; Kulkarni K; Aaltonen ET; Horn JC; Hickey RM; Taslakian B
    J Vasc Interv Radiol; 2020 Aug; 31(8):1233-1241. PubMed ID: 32741550
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In intermediate stage hepatocellular carcinoma: radioembolization with yttrium 90 or chemoembolization?
    El Fouly A; Ertle J; El Dorry A; Shaker MK; Dechêne A; Abdella H; Mueller S; Barakat E; Lauenstein T; Bockisch A; Gerken G; Schlaak JF
    Liver Int; 2015 Feb; 35(2):627-35. PubMed ID: 25040497
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Liver-directed treatments of liver-dominant metastatic leiomyosarcoma.
    Krzyston H; Morse B; Deperalta D; Rishi A; Kayaleh R; El-Haddad G; Smith J; Druta M; Kis B
    Diagn Interv Radiol; 2020 Sep; 26(5):449-455. PubMed ID: 32673206
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Radioembolization Followed by Transarterial Chemoembolization in Hepatocellular Carcinoma.
    Vardar BU; Meram E; Karaoglu K; Liang M; Yu M; Laeseke P; Ozkan OS
    Cureus; 2022 Apr; 14(4):e23783. PubMed ID: 35518553
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biomarkers associated with survival and favourable outcome of radioembolization with yttrium-90 glass microspheres for colon cancer liver metastases: Single centre experience.
    Triviño-Ibáñez EM; Pardo Moreno P; Ciampi Dopazo JJ; Ramos-Font C; Ruiz Villaverde G; González-Flores E; Navarro Vergara PF; Rashki M; Gómez-Río M; Rodríguez-Fernández A
    Rev Esp Med Nucl Imagen Mol (Engl Ed); 2022; 41(4):231-238. PubMed ID: 34454892
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.